Please assess the completion status of the following clinical trial:

Trial Title: Trial Comparing High Versus Standard Dose Oseltamivir in Severe Influenza Infection in ICU

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients age 12 and older and 45 kg or more~2. Suspected or confirmed influenza (Appendix A)~3. Requirement for ICU admission due to respiratory distress or critical illness defined as one of:~   1. Inspired oxygen need of \>50% for at least 4 hours (For FiO2 for non-intubated patients see Appendix B)~  2. mechanical ventilation~  3. Patient is receiving inotrope or vasopressor~4. Negative b-HCG test or negative bedside urine test pending a confirmatory b-HCG test for pregnancy in women of childbearing age (12-60 years of age) will allow study entry~Exclusion Criteria:~1. Inability to obtain consent~2. Patients receiving more than two doses of 150 mg or higher oseltamivir in 36 hours before study entry~3. Patients having received more than 3 doses of 75 mg oseltamivir immediately in 36 hours before study entry~4. Age less than 12 years, or age \<16 and weight less than 45 kg~5. Unlikely to absorb enteral study drug (e.g. patients with partial or complete mechanical bowel obstruction, intestinal ischemia, infarction, and short bowel syndrome)~6. Known allergy or hypersensitivity to oseltamivir~7. Pregnancy or breast feeding~8. Previous enrollment in current study~9. Concurrent involvement in an RCT examining an antiviral agent including other neuraminidase inhibitors, interferon-a and/or ribavirin~10. Chronic renal failure requiring chronic hemodialysis~11. Severe chronic liver disease (Child-Pugh Score 11-15)~12. Anticipated death within 24 hours as judged by attending physician or local PI~13. Patient carrying do not intubate order (a no CPR or no defibrillate or no chest compressions order alone is allowed)

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard Oseltamivir dose 75 mg bid (Type: ACTIVE_COMPARATOR): Standard dosing
- High Dose Oseltamivir arm 225mg bid (Type: EXPERIMENTAL): High dose arm of the study

Based on this trial design, predict the completion outcome and termination type (if applicable).